Andere talen Awakn Life Sciences Corp.

Aandelen

AWKN

CA05455W1086

Beurs gesloten - Canadian Securities Exchange Andere beurzen 20:42:10 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,195 ^CAD	-7,14%		0,00%	+34,48%

03/04	Awakn Life Sciences Corp. kondigt de lancering aan van een licentiepartnerschapsovereenkomst met Rivus Wellness and Research Institute	CI
24/01	Awakn Life Sciences Corp. Wijst programma AWKN-002 aan voor stoornis in alcoholgebruik op de Amerikaanse markt	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CSE Bulletin: Suspensions - AWKN, BHCC, BZAM, GLOW, VTAL, JKPT, MEAL,VFI.X, STHZ	08/05
Canadian Investment Regulatory Organization Trading Halt - AWKN	08/05
Awakn Life Sciences Discusses Filing of Financial Statements	03/05
Awakn Life Sciences Announces Closing of Tranche of Private Placement	17/04
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic	03/04
Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	03/04
Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	03/04
Canadian Securities Exchange Reports February 2024 Performance Figures	15/03
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)	12/02
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange	12/02
Awakn Life Sciences Announces Conditional Approval of CSE Listing	05/02
Awakn Life Sciences Corp. Designates Program AWKN-002 for Alcohol Use Disorder in the US Market	24/01
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers	24/01
Awakn Life Sciences Corp. Enters Global Licensing Agreement with LTS Lohmann Therapie-Systeme AG	20/12
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS	20/12
Awakn Life Sciences Provides Corporate Update	15/12
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	14/12
Awakn Life Sciences Corp. Receives Clinical Trial Authorization from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority in the UK for a Phase III Clinical Trial for its Lead Program AWKN-P001 for the Treatment of Severe Alcohol Use Disorder	15/11
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001	15/11
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements	10/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Awakn Life Sciences Corp.

Aandelen

AWKN

CA05455W1086

Andere talen

Filters